Explore

Janux Therapeutics Initiates Phase 1 Study for JANX013 in Metastatic Prostate Cancer

Janux Therapeutics Initiates Phase 1 Study for JANX013 in Metastatic Prostate Cancer

Janux Therapeutics Initiates Phase 1 Study for JANX013 in Metastatic Prostate Cancer

AI Virtual Cell Predicts Personalized Breast Cancer Treatments Using Protein Dynamics

AI Virtual Cell Predicts Personalized Breast Cancer Treatments Using Protein Dynamics

A new AI tool named ProteinTalks has been developed to predict the effectiveness of drugs against cancer cells, identify new drug combinations, and pinpoint proteins linked to drug resistance. This AI virtual cell utilizes protein dynamics by tracking how protein levels shift over time in response to treatment. Researchers captured over 38 million protein measurements from 18 breast cancer cell lines, observing their responses to 63 FDA-approved anticancer drugs and 59 two-drug combinations at various time points (before treatment, 6, 24, and 48 hours). ProteinTalks was trained on this time-resolved dataset, allowing it to learn the dynamic changes in protein levels as drugs take effect. The tool demonstrated superior performance compared to existing AI models based on gene activity and traditional machine-learning methods in predicting drug responses.

Experimental CAR T-Cell Therapy Achieves Complete Remission in 3-Year-Old with Metastatic Liver Cancer

Experimental CAR T-Cell Therapy Achieves Complete Remission in 3-Year-Old with Metastatic Liver Cancer

An experimental Chimeric Antigen Receptor (CAR) T-cell therapy has achieved a complete regression of hepatoblastoma, a malignant liver cancer, in a 3-year-old boy with metastatic disease. The patient, who had previously undergone multiple rounds of chemotherapy and surgeries, experienced a rapid recurrence of cancer that had spread to his lungs and potentially bones. He was enrolled in the CARE study, an early-phase human trial, and received two doses of GPC3-CAR treatment. This therapy involved engineering his own T-cells to recognize glypican-3 (GPC3), a protein highly expressed in liver cancers, and boosting their longevity and tumor-killing ability with immune proteins interleukin-15 and interleukin-21. After the first infusion, the patient showed a partial response, and following a second dose eight weeks later, follow-up scans revealed no remaining signs of the disease, with the boy remaining disease-free after 12 months. This case, reported in The New England Journal of Medicine, demonstrates the po...

AI Tool Successfully Predicts Immunotherapy Outcomes in Lung Cancer Patients

AI Tool Successfully Predicts Immunotherapy Outcomes in Lung Cancer Patients

A new study published in Nature Medicine reveals that artificial intelligence (AI) tools can accurately predict treatment and survival outcomes for patients with advanced non-small cell lung cancer (NSCLC) undergoing immunotherapy. The I3LUNG project, an international trial, developed these AI-based predictive models to personalize therapeutic approaches for individuals. Immunotherapy, while transformative for some lung cancer patients, often faces resistance, and current predictive biomarkers like PD-L1 expression have limitations. Dr. Marina Garassino, professor of medicine at UChicago Medicine and senior author, emphasized the need for smarter tools. The research team enrolled 2,396 NSCLC patients from six international centers, including the United States, integrating diverse data such as clinical, imaging, pathology, and genomic information. The AI models consistently outperformed standard clinical biomarkers, with one model achieving an AUC score of 0.88 when incorporating clinical, blood, imaging, a...

FDA Approves Reduced Monitoring Time for Amgen's IMDELLTRA in Small Cell Lung Cancer Treatment

FDA Approves Reduced Monitoring Time for Amgen's IMDELLTRA in Small Cell Lung Cancer Treatment

The U.S. Food and Drug Administration (FDA) has approved an update to the prescribing information for Amgen's IMDELLTRA® (tarlatamab-dlle), significantly reducing the recommended monitoring time for the first two doses of the treatment. Patients receiving IMDELLTRA will now require monitoring for 6 to 8 hours from the start of their first two infusions, a substantial decrease from the previous recommendation of 22 to 24 hours. Additionally, patients will undergo a follow-up assessment, including vital signs, the day after each of these initial two doses. This change is specifically for individuals with extensive-stage small cell lung cancer (ES-SCLC), an aggressive form of lung cancer where most patients experience disease progression after first-line treatment. The update aims to alleviate the burden on patients and care centers by simplifying the initial treatment period and potentially making the therapy more accessible in community oncology practices, where a majority of U.S. cancer patients receive ca...

Adelaide University Researchers Reprogram Immune Cells to Combat Solid Tumors Using Nanoparticle Technology

Adelaide University Researchers Reprogram Immune Cells to Combat Solid Tumors Using Nanoparticle Technology

Researchers at Adelaide University have developed a novel method utilizing messenger RNA (mRNA) technology and targeted lipid nanoparticles to reprogram tumor-associated macrophages (TAMs), a type of immune cell that typically helps tumors evade the body's defenses. This approach, detailed in Science Advances, aims to alter the tumor microenvironment rather than destroy immune cells. The nanoparticles are coated with an antibody that binds to TREM2, a protein highly expressed on TAMs, ensuring precise delivery. Once inside the macrophages, the particles release an mRNA molecule that instructs the cells to produce the chemokine CXCL9, and a compound called Resiquimod. Resiquimod prompts the macrophages to switch from an immune-suppressing state, while CXCL9 acts as a chemical beacon to attract cancer-fighting CD8+ T cells into the tumor. Preclinical animal models showed that this treatment reduced immune-suppressing macrophages by over 60% and increased CXCL9 levels fourfold, leading to greater infiltration...

DLA Piper Advises TwoStep Therapeutics in $62.5 Million Series A Financing for Solid Tumor Therapies

DLA Piper Advises TwoStep Therapeutics in $62.5 Million Series A Financing for Solid Tumor Therapies

DLA Piper Advises TwoStep Therapeutics in $62.5 Million Series A Financing for Solid Tumor Therapies

Arm Holdings CEO Rene Haas Predicts AI Will Cure Cancer, Drawing Expert Criticism

Arm Holdings CEO Rene Haas Predicts AI Will Cure Cancer, Drawing Expert Criticism

Arm Holdings CEO Rene Haas Predicts AI Will Cure Cancer, Drawing Expert Criticism

Viva Biotech Discusses Challenges and Opportunities in Cyclic Peptide Drug Development and Manufacturing

Viva Biotech Discusses Challenges and Opportunities in Cyclic Peptide Drug Development and Manufacturing

Viva Biotech Discusses Challenges and Opportunities in Cyclic Peptide Drug Development and Manufacturing

CU Anschutz Advances Precision Medicine for Rare Cancers with Organoid Platform

CU Anschutz Advances Precision Medicine for Rare Cancers with Organoid Platform

The University of Colorado Anschutz Medical Campus is developing a functional precision medicine platform aimed at personalizing treatments for rare cancers. Led by Alice Soragni, PhD, a professor of Biomedical Informatics and Neurosurgery and the Marsico Chair in Excellence in Functional Precision Medicine, the initiative focuses on creating patient-derived tumor organoids. These miniature 'tumor avatars,' grown from a patient's own tumor cells, are used to test responses to various drugs. The platform, detailed in Nature Protocols, utilizes label-free imaging and artificial intelligence to continuously track individual organoid responses, identifying differences that conventional methods might miss. The goal is to integrate this organoid testing into clinical care, moving it from a research tool to a validated clinical assay that can inform treatment decisions for patients with hard-to-treat tumors. This approach is particularly crucial for rare cancers, where standard treatments are often non-existent d...

UCSF Advances Precision Medicine for Pediatric Sarcoma and Osteosarcoma

UCSF Advances Precision Medicine for Pediatric Sarcoma and Osteosarcoma

UCSF Benioff Children's Hospitals are actively working to expand treatment options for pediatric sarcoma and osteosarcoma, conditions for which outcomes have remained largely unchanged for decades. Researchers, including pediatric hematologist-oncologist Amanda Marinoff, MD, are moving away from a 'one-size-fits-all' approach towards precision medicine. This involves tailoring therapy based on a patient's risk and tumor biology. A key component of this strategy is leveraging the UCSF500 DNA and RNA sequencing platform, which is already integrated into clinical care at UCSF. This platform allows physicians to define molecular features that guide diagnoses, prognoses, and treatment decisions. Additionally, UCSF is participating in the CaIRS (Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas) phase 1 trial, exploring a new drug combination for these cancers, and is part of a $15 million multi-institutional grant from Break Through Cancer focused on osteosarcoma.

NIH-Funded Research Develops Bone Marrow-on-a-Chip Model for Immune Cell Study

NIH-Funded Research Develops Bone Marrow-on-a-Chip Model for Immune Cell Study

Scientists from Georgia Tech and Vanderbilt University, with support from the National Institutes of Health (NIH), have created a novel laboratory model known as a 'bone marrow-on-a-chip.' This advanced platform is designed to observe how antibody-producing plasma cells migrate, mature, and survive within human bone marrow. The model integrates a lymph node-mimicking organoid with a tissue chip that replicates bone marrow conditions. Researchers isolated B cells from human tonsil tissue and blood, growing them in a lymphoid tissue-like environment. Inactivated influenza virus was used to facilitate the transformation of B cells into antibody-secreting plasma cells. Concurrently, a microfluidics-based vascularized microenvironment was developed to mimic the structural and functional aspects of human bone marrow. The final model is assembled within a stack of 96-well plastic plates, featuring multiple channels coated with a gel-like material containing nutrients and growth factors. It replicates both the end...